Profil
Christophe Douat is the founder of MedinCell SA, serving as Chief Executive Officer & Director since 2003.
Mr. Douat is also the founder of Matignon Technologies II FCPR.
Current jobs include Chairman at Great North SARL and Director at CM Biomaterials BV.
Former jobs include Director-Stakes at Matignon Investissement et Gestion SAS from 2001 to 2010, Director at Arterial Remodelling Technologies SA, Director at Groupement International d'Informatique de Santé SA, Member-Supervisory Board at Nanobiotix SA from 2011 to 2017, Member-Supervisory Board at Nanobiotix SA from 2006 to 2009, General Manager at Sabourin Lake Lodge from 1992 to 1997, and Venture Partner at Matignon Technologies from 2001 to 2009.
Education includes a graduate degree from the University of Minnesota, an MBA from the University of Calgary, and an undergraduate degree from École Nationale Supérieure des Mines de Paris.
Aktive Positionen von Christophe Douat
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDINCELL S.A. | Gründer | 09.01.2003 |
Great North SARL | Vorsitzender | - |
CM Biomaterials BV
CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing Manufactures plastic products | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Christophe Douat
| Unternehmen | Position | Ende |
|---|---|---|
| NANOBIOTIX | Direktor/Vorstandsmitglied | 01.01.2017 |
Matignon Investissement et Gestion SAS
Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression. | Private Equity Investor | 01.05.2010 |
Matignon Technologies | Corporate Officer/Principal | 01.04.2009 |
| NANOBIOTIX | Direktor/Vorstandsmitglied | 01.01.2009 |
Sabourin Lake Lodge | Corporate Officer/Principal | 01.01.1997 |
Ausbildung von Christophe Douat
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Matignon Investissement et Gestion SAS
Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression. | Finance |
University of Minnesota
University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Calgary
University of Calgary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
École Nationale Supérieure des Mines de Paris
École Nationale Supérieure des Mines de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Matignon Technologies II FCPR
Matignon Technologies II FCPR Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Arterial Remodelling Technologies SA
Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Develops bioresorbable peripheral and coronary polymer stents | Health Technology |
Nanobiotix SA
Nanobiotix SA Pharmaceuticals: MajorHealth Technology Develops and manufactures nanotherapeutics for treatment of cancer | Health Technology |
Groupement International d'Informatique de Santé SA
Groupement International d'Informatique de Santé SA Publishing: Books/MagazinesConsumer Services Engages in the management of an online health and nutrition portal | Consumer Services |
MedinCell SA
MedinCell SA Pharmaceuticals: MajorHealth Technology Provides therapeutic solutions | Health Technology |
Great North SARL | |
CM Biomaterials BV
CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing Manufactures plastic products | Producer Manufacturing |
Sabourin Lake Lodge | |
Matignon Technologies |
















